GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (LTS:0GTN) » Definitions » Debt-to-Revenue

BioGaia AB (LTS:0GTN) Debt-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

BioGaia AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0 Mil. BioGaia AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0 Mil. BioGaia AB's annualized Revenue for the quarter that ended in Dec. 2023 was kr1,191 Mil. BioGaia AB's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


BioGaia AB Debt-to-Revenue Historical Data

The historical data trend for BioGaia AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Debt-to-Revenue Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 - -

BioGaia AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioGaia AB's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Debt-to-Revenue falls into.



BioGaia AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

BioGaia AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 1296.505
=0.00

BioGaia AB's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 1191.092
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


BioGaia AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB (LTS:0GTN) Business Description

Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

BioGaia AB (LTS:0GTN) Headlines

No Headlines